Harambat Jérôme, Bonthuis Marjolein, van Stralen Karlijn J, Ariceta Gema, Battelino Nina, Bjerre Anna, Jahnukainen Timo, Leroy Valérie, Reusz György, Sandes Ana R, Sinha Manish D, Groothoff Jaap W, Combe Christian, Jager Kitty J, Verrina Enrico, Schaefer Franz
Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Clin J Am Soc Nephrol. 2014 Jan;9(1):92-9. doi: 10.2215/CJN.00890113. Epub 2013 Oct 31.
Growth and final height are of major concern in children with ESRD. This study sought to describe the distribution of adult height of patients who started renal replacement therapy (RRT) during childhood and to identify determinants of final height in a large cohort of RRT children.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 1612 patients from 20 European countries who started RRT before 19 years of age and reached final height between 1990 and 2011 were included. Linear regression analyses were performed to calculate adjusted mean final height SD score (SDS) and to investigate its potential determinants.
The median final height SDS was -1.65 (median of 168 cm in boys and 155 cm in girls). Fifty-five percent of patients attained an adult height within the normal range. Adjusted for age at start of RRT and primary renal diseases, final height increased significantly over time from -2.06 SDS in children who reached adulthood in 1990-1995 to -1.33 SDS among those reaching adulthood in 2006-2011. Older age at start of RRT, more recent period of start of RRT, cumulative percentage time on a functioning graft, and greater height SDS at initiation of RRT were independently associated with a higher final height SDS. Patients with congenital anomalies of the kidney and urinary tract and metabolic disorders had a lower final height than those with other primary renal diseases.
Although final height remains suboptimal in children with ESRD, it has consistently improved over time.
生长及最终身高是终末期肾病(ESRD)患儿主要关注的问题。本研究旨在描述儿童期开始肾脏替代治疗(RRT)的患者的成人身高分布情况,并确定一大群接受RRT治疗儿童的最终身高的决定因素。
设计、地点、参与者及测量方法:纳入了来自20个欧洲国家的1612例患者,这些患者在19岁之前开始接受RRT治疗,并在1990年至2011年间达到最终身高。进行线性回归分析以计算调整后的平均最终身高标准差评分(SDS),并研究其潜在决定因素。
最终身高SDS的中位数为-1.65(男孩中位数为168cm,女孩中位数为155cm)。55%的患者成人身高在正常范围内。在调整了开始RRT时的年龄和原发性肾脏疾病后,最终身高随时间显著增加,从1990 - 1995年成年的儿童的-2.06 SDS增加到2006 - 2011年成年的儿童的-1.33 SDS。开始RRT时年龄较大、开始RRT的时间更近、移植肾发挥功能的累计时间百分比以及开始RRT时较高的身高SDS与较高的最终身高SDS独立相关。患有肾脏和尿路先天性异常以及代谢紊乱的患者的最终身高低于患有其他原发性肾脏疾病的患者。
尽管ESRD患儿的最终身高仍未达到最佳状态,但随着时间的推移一直在持续改善。